Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis
Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and...
- Autores:
-
Salazar, Juan
Pirela, Daniela
Nava, Manuel
Castro, Ana
Angarita, Lissé
Parra, Heliana
Durán-Agüero, Samuel
Rojas-Gómez, Diana Marcela
Galbán, Néstor
Añez, Roberto
Chacín, Maricarmen
Diaz, Andrea
Villasmil, Nelson
Bautista De Sanctis, Juan
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2022
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/11286
- Palabra clave:
- specialized proresolving mediators
inflammation
resolution
Atherosclerosis
Intimal hyperplasia
Reperfusion injury
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
| id |
USIMONBOL2_db38a0356b4636787d17b4a570164429 |
|---|---|
| oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/11286 |
| network_acronym_str |
USIMONBOL2 |
| network_name_str |
Repositorio Digital USB |
| repository_id_str |
|
| dc.title.eng.fl_str_mv |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| title |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| spellingShingle |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis specialized proresolving mediators inflammation resolution Atherosclerosis Intimal hyperplasia Reperfusion injury |
| title_short |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| title_full |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| title_fullStr |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| title_full_unstemmed |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| title_sort |
Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis |
| dc.creator.fl_str_mv |
Salazar, Juan Pirela, Daniela Nava, Manuel Castro, Ana Angarita, Lissé Parra, Heliana Durán-Agüero, Samuel Rojas-Gómez, Diana Marcela Galbán, Néstor Añez, Roberto Chacín, Maricarmen Diaz, Andrea Villasmil, Nelson Bautista De Sanctis, Juan Bermúdez, Valmore |
| dc.contributor.author.none.fl_str_mv |
Salazar, Juan Pirela, Daniela Nava, Manuel Castro, Ana Angarita, Lissé Parra, Heliana Durán-Agüero, Samuel Rojas-Gómez, Diana Marcela Galbán, Néstor Añez, Roberto Chacín, Maricarmen Diaz, Andrea Villasmil, Nelson Bautista De Sanctis, Juan Bermúdez, Valmore |
| dc.subject.eng.fl_str_mv |
specialized proresolving mediators inflammation resolution Atherosclerosis Intimal hyperplasia Reperfusion injury |
| topic |
specialized proresolving mediators inflammation resolution Atherosclerosis Intimal hyperplasia Reperfusion injury |
| description |
Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD. |
| publishDate |
2022 |
| dc.date.accessioned.none.fl_str_mv |
2022-11-10T13:31:14Z |
| dc.date.available.none.fl_str_mv |
2022-11-10T13:31:14Z |
| dc.date.issued.none.fl_str_mv |
2022 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.driver.eng.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.spa.spa.fl_str_mv |
Artículo científico |
| dc.identifier.citation.eng.fl_str_mv |
Salazar, J., Pirela, D., Nava, M., Castro, A., Angarita, L., Parra, H., Durán-Agüero, S., Rojas-Gómez, D. M., Galbán, N., Añez, R., Chacín, M., Diaz, A., Villasmil, N., De Sanctis, J. B., & Bermúdez, V. (2022). Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. International Journal of Molecular Sciences, 23(6), 3133. https://doi.org/10.3390/ijms23063133 |
| dc.identifier.issn.none.fl_str_mv |
14220067 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/11286 |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3390/ijms23063133 |
| identifier_str_mv |
Salazar, J., Pirela, D., Nava, M., Castro, A., Angarita, L., Parra, H., Durán-Agüero, S., Rojas-Gómez, D. M., Galbán, N., Añez, R., Chacín, M., Diaz, A., Villasmil, N., De Sanctis, J. B., & Bermúdez, V. (2022). Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. International Journal of Molecular Sciences, 23(6), 3133. https://doi.org/10.3390/ijms23063133 14220067 |
| url |
https://hdl.handle.net/20.500.12442/11286 https://doi.org/10.3390/ijms23063133 |
| dc.language.iso.eng.fl_str_mv |
eng |
| language |
eng |
| dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.eng.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.mimetype.spa.fl_str_mv |
pdf |
| dc.publisher.eng.fl_str_mv |
MDPI |
| dc.source.eng.fl_str_mv |
International Journal of Molecular Sciences |
| dc.source.none.fl_str_mv |
Vol. 23, No.6 (2022) |
| institution |
Universidad Simón Bolívar |
| bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/77ebab91-2782-45fe-9fc8-78397fb44701/download https://bonga.unisimon.edu.co/bitstreams/8fd080b9-e285-41e7-9134-d3b7dedd7504/download https://bonga.unisimon.edu.co/bitstreams/48ca96bc-186b-4d28-bd70-ae4851ee28c6/download https://bonga.unisimon.edu.co/bitstreams/ea651e9f-21de-47fe-8c3e-dd5d8c431211/download https://bonga.unisimon.edu.co/bitstreams/0f90e57a-28ab-40fe-96ef-b43c4e5805ec/download |
| bitstream.checksum.fl_str_mv |
6920618a1c5997240d35e7cb8171ea47 4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 5e974b4c06cbb4648ab82c51491feb22 ee68bde9bfb94a66dd6b4a47aeea4c7a |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
DSpace UniSimon |
| repository.mail.fl_str_mv |
bibliotecas@biteca.com |
| _version_ |
1803705558978527232 |
| spelling |
Salazar, Juanfbd053e7-5aea-424c-812f-92153ecb9181Pirela, Danielaed55bbd8-afa8-4481-aef4-c6124b3eb9d2Nava, Manuele695cfca-ba32-4833-92b3-e55a0c073a68Castro, Ana608db2bd-da0c-4bd8-b961-26e92ff69042Angarita, Lissé5bee697d-7d35-4c70-8cbb-8e986174ce25Parra, Heliana746f7708-c6d0-4b88-a9f3-df07d9c646fcDurán-Agüero, Samuel1f895507-4c22-4ebb-9b65-858b9eef76d4Rojas-Gómez, Diana Marcelabee2257a-bc9b-4fc9-9cab-85288c411490Galbán, Néstor1aa6030f-0c48-4ff7-a4ad-8c486cb53165Añez, Roberto0a8ecfdc-a89a-4435-9859-b66bba8947faChacín, Maricarmen5c3b3d7c-4444-47e2-b2be-11f08df10409Diaz, Andrea95e94541-6d15-4b72-a7f3-454481cbafaaVillasmil, Nelson700a94ed-66d4-4011-967f-dffaa90ec650Bautista De Sanctis, Juan1e61cc59-e1bc-48f8-a654-361d27a745c1Bermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663a2022-11-10T13:31:14Z2022-11-10T13:31:14Z2022Salazar, J., Pirela, D., Nava, M., Castro, A., Angarita, L., Parra, H., Durán-Agüero, S., Rojas-Gómez, D. M., Galbán, N., Añez, R., Chacín, M., Diaz, A., Villasmil, N., De Sanctis, J. B., & Bermúdez, V. (2022). Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. International Journal of Molecular Sciences, 23(6), 3133. https://doi.org/10.3390/ijms2306313314220067https://hdl.handle.net/20.500.12442/11286https://doi.org/10.3390/ijms23063133Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.pdfengMDPIAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2International Journal of Molecular SciencesVol. 23, No.6 (2022)specialized proresolving mediatorsinflammationresolutionAtherosclerosisIntimal hyperplasiaReperfusion injurySpecialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosisinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1Capó, X.; Martorell, M.; Busquets-Cortés, C.; Tejada, S.; Tur, J.A.; Pons, A.; Sureda, A. Resolvins as proresolving inflammatory mediators in cardiovascular disease. Eur. J. Med. Chem. 2018, 153, 123–130. [CrossRef] [PubMed]World Health Organization. Cardiovascular Diseases (CVDs). Available online: https://www.who.int/news-room/fact-sheets/ detail/cardiovascular-diseases-(cvds) (accessed on 18 August 2021).Recchiuti, A.; Serhan, C.N. Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation. Front. Immunol. 2012, 3, 298. [CrossRef] [PubMed]Sugimoto, M.A.; Sousa, L.P.; Pinho, V.; Perretti, M.; Teixeira, M.M. Resolution of Inflammation: What Controls Its Onset? Front. Immunol. 2016, 7, 160. [CrossRef]Nathan, C.; Ding, A. Nonresolving Inflammation. Cell 2010, 140, 871–882. [CrossRef]Headland, S.E.; Norling, L.V. The resolution of inflammation: Principles and challenges. Semin. Immunol. 2015, 27, 149–160. [CrossRef]Serhan, C.N.; Chiang, N.; Van Dyke, T.E. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8, 349–361. [CrossRef]Buckley, C.D.; Gilroy, D.W.; Serhan, C.N. Pro-Resolving lipid mediators and Mechanisms in the resolution of acute inflammation. Immunity 2014, 40, 315–327. [CrossRef]Basil, M.C.; Levy, B.D. Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation. Nat. Rev. Immunol. 2016, 16, 51–67. [CrossRef]Park, J.; Langmead, C.J.; Riddy, D.M. New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery. ACS Pharmacol. Transl. Sci. 2020, 3, 88–106. [CrossRef]Doran, A.C. Inflammation Resolution: Implications for Atherosclerosis. Circ. Res. 2022, 130, 130–148. [CrossRef]de Gaetano, M.; McEvoy, C.; Andrews, D.; Cacace, A.; Hunter, J.; Brennan, E.; Godson, C. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Front. Pharmacol. 2018, 9, 1488. [CrossRef] [PubMed]Doyle, R.; Sadlier, D.M.; Godson, C. Pro-resolving lipid mediators: Agents of anti-ageing? Semin. Immunol. 2018, 40, 36–48. [CrossRef] [PubMed]Viola, J.R.; Lemnitzer, P.; Jansen, Y.; Csaba, G.; Winter, C.; Neideck, C.; Silvestre-Roig, C.; Dittmar, G.; Döring, Y.; Drechsler, M.; et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice. Circ. Res. 2016, 119, 1030–1038. [CrossRef] [PubMed]Fredman, G.; Spite, M. Specialized pro-resolving mediators in cardiovascular diseases. Mol. Asp. Med. 2017, 58, 65–71. [CrossRef]Kasikara, C.; Doran, A.C.; Cai, B.; Tabas, I. The role of non-resolving inflammation in atherosclerosis. J. Clin. Investig. 2018, 128, 2713–2723. [CrossRef]Satish, M.; Agrawal, D.K. Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases. Expert Rev. Cardiovasc. Ther. 2019, 17, 177–184. [CrossRef]Halade, G.V.; Black, L.M.; Verma, M. Paradigm shift—Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery. Biotechnol. Adv. 2018, 36, 935–953. [CrossRef]Halade, G.V.; Kain, V.; Ingle, K.A.; Prabhu, S.D. Interaction of 12/15-lipoxygenase with fatty acids alters the leukocyte kinetics leading to improved postmyocardial infarction healing. Am. J. Physiol. Heart Circ. Physiol. 2017, 313, H89–H102. [CrossRef]Halade, G.V.; Kain, V.; Tourki, B.; Jadapalli, J.K. Lipoxygenase drives lipidomic and metabolic reprogramming in ischemic heart failure. Metabolism 2019, 96, 22–32. [CrossRef]Chiang, N.; Serhan, C.N. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol. Asp. Med. 2017, 58, 114–129. [CrossRef] [PubMed]Bang, S.; Xie, Y.-K.; Zhang, Z.-J.; Wang, Z.; Xu, Z.-Z.; Ji, R.-R. GPR37 regulates macrophage phagocytosis and resolution of inflammatory pain. J. Clin. Investig. 2018, 128, 3568–3582. [CrossRef] [PubMed]Dalli, J.; Serhan, C.N. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br. J. Pharmacol. 2019, 176, 1024–1037. [CrossRef] [PubMed]Dalli, J.; Serhan, C.N. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br. J. Pharmacol. 2019, 176, 1024–1037. [CrossRef] [PubMed]Han, Y.-H.; Lee, K.; Saha, A.; Han, J.; Choi, H.; Noh, M.; Lee, Y.-H.; Lee, M.-O. Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders. Biomol. Ther. 2021, 29, 455–464. [CrossRef]Kang, G.J.; Kim, E.J.; Lee, C.H. Therapeutic Effects of Specialized Pro-Resolving Lipids Mediators on Cardiac Fibrosis via NRF2 Activation. Antioxidants 2020, 9, 1259. [CrossRef]Recchiuti, A. Resolvin D1 and its GPCRs in resolution circuits of inflammation. Prostaglandins Other Lipid Mediat. 2013, 107, 64–76.McCrary, M.R.; Jiang, M.Q.; Giddens, M.M.; Zhang, J.Y.; Owino, S.; Wei, Z.Z.; Zhong, W.; Gu, X.; Xin, H.; Hall, R.A.; et al. Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice. FASEB J. 2019, 33, 10680–10691.McCrary, M.R.; Jiang, M.Q.; Giddens, M.M.; Zhang, J.Y.; Owino, S.; Wei, Z.Z.; Zhong, W.; Gu, X.; Xin, H.; Hall, R.A.; et al. Protective effects of GPR37 via regulation of inflammation and multiple cell death pathways after ischemic stroke in mice. FASEB J. 2019, 33, 10680–10691.Dalli, J.; Serhan, C.N. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol. 2017, 8, 1400.Dalli, J.; Serhan, C.N. Pro-Resolving Mediators in Regulating and Conferring Macrophage Function. Front. Immunol. 2017, 8, 1400. [CrossRef]Yokomizo, T. Two distinct leukotriene B4 receptors, BLT1 and BLT2. J. Biochem. 2015, 157, 65–71. [CrossRef]Colas, R.A.; Dalli, J.; Chiang, N.; Vlasakov, I.; Sanger, J.M.; Riley, I.R.; Serhan, C.N. Identification and Actions of the Maresin 1 Metabolome in Infectious Inflammation. J. Immunol. 2016, 197, 4444–4452. [CrossRef]Chiang, N.; Libreros, S.; Norris, P.C.; De La Rosa, X.; Serhan, C.N. Maresin 1 activates LGR6 receptor promoting phagocyte immunoresolvent functions. J. Clin. Investig. 2019, 129, 5294–5311. [CrossRef] [PubMed]Flak, M.B.; Koenis, D.S.; Sobrino, A.; Smith, J.; Pistorius, K.; Palmas, F.; Dalli, J. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections. J. Clin. Investig. 2020, 130, 359–373. [CrossRef] [PubMed]Chattopadhyay, R.; Mani, A.M.; Singh, N.K.; Rao, G.N. Resolvin D1 blocks H2O2-mediated inhibitory crosstalk between SHP2 and PP2A and suppresses endothelial-monocyte interactions. Free Radic. Biol. Med. 2018, 117, 119–131. [CrossRef] [PubMed]Chattopadhyay, R.; Raghavan, S.; Rao, G.N. Resolvin D1 via prevention of ROS-mediated SHP2 inactivation protects endothelial adherens junction integrity and barrier function. Redox Biol. 2017, 12, 438–455. [CrossRef]Carracedo, M.; Artiach, G.; Arnardottir, H.; Bäck, M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin. Immunopathol. 2019, 41, 757–766. [CrossRef]Krishnamoorthy, S.; Recchiuti, A.; Chiang, N.; Yacoubian, S.; Lee, C.-H.; Yang, R.; Petasis, N.A.; Serhan, C.N. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 2010, 107, 1660–1665. [CrossRef]So, J.; Wu, D.; Lichtenstein, A.H.; Tai, A.K.; Matthan, N.R.; Maddipati, K.R.; Lamon-Fava, S. EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study. Atherosclerosis 2020, 316, 90–98. [CrossRef]Lopez, E.F.; Kabarowski, J.H.; Ingle, K.A.; Kain, V.; Barnes, S.; Crossman, D.; Lindsey, M.; Halade, G.V. Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction. Am. J. Physiol. Circ. Physiol. 2015, 308, H269–H280. [CrossRef]Halade, G.V.; Kain, V.; Black, L.M.; Prabhu, S.D.; Ingle, K.A. Aging dysregulates D- and E-series resolvins to modulate cardios- plenic and cardiorenal network following myocardial infarction. Aging 2016, 8, 2611–2634. [CrossRef]Jadapalli, J.K.; Wright, G.W.; Kain, V.; Sherwani, M.A.; Sonkar, R.; Yusuf, N.; Halade, G.V. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium. Am. J. Physiol. Circ. Physiol. 2018, 315, H1091–H1100. [CrossRef]Halade, G.V.; Kain, V.; Wright, G.M.; Jadapalli, J.K. Subacute treatment of carprofen facilitate splenocardiac resolution deficit in cardiac injury. J. Leukoc. Biol. 2018, 104, 1173–1186. [CrossRef] [PubMed]Kain, V.; Jadapalli, J.K.; Tourki, B.; Halade, G.V. Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure. Pharmacol. Res. 2019, 146, 104295. [CrossRef] [PubMed]Brennan, E.; Kantharidis, P.; Cooper, M.E.; Godson, C. Pro-resolving lipid mediators: Regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 2021, 17, 725–739. [CrossRef] [PubMed]Jadapalli, J.K.; Halade, G.V. Unified nexus of macrophages and maresins in cardiac reparative mechanisms. FASEB J. 2018, 32, 5227–5237. [CrossRef] [PubMed]Chandrasekharan, J.A.; Sharma-Walia, N. Lipoxins: Nature’s way to resolve inflammation. J. Inflamm. Res. 2015, 8, 181–192.Ho, K.J.; Spite, M.; Owens, C.D.; Lancero, H.; Kroemer, A.H.; Pande, R.; Creager, M.A.; Serhan, C.N.; Conte, M.S. Aspirin- Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. Am. J. Pathol. 2010, 177, 2116–2123. [CrossRef]Ho, K.J.; Spite, M.; Owens, C.D.; Lancero, H.; Kroemer, A.H.; Pande, R.; Creager, M.A.; Serhan, C.N.; Conte, M.S. Aspirin- Triggered Lipoxin and Resolvin E1 Modulate Vascular Smooth Muscle Phenotype and Correlate with Peripheral Atherosclerosis. Am. J. Pathol. 2010, 177, 2116–2123. [CrossRef]Rafieian-Kopaei, M.; Setorki, M.; Doudi, M.; Baradaran, A.; Nasri, H. Atherosclerosis: Process, Indicators, Risk Factors and New Hopes. Int. J. Prev. Med. 2014, 5, 927–946.Fredman, G.; Tabas, I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am. J. Pathol. 2017, 187, 1211–1221. [CrossRef]Rojas, J.; Salazar, J.; Martínez, M.S.; Palmar, J.; Bautista, J.; Chávez-Castillo, M.; Gómez, A.; Bermudez, V. Macrophage Heterogene- ity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis. Scientifica 2015, 2015, 1–17. [CrossRef]Viola, J.; Soehnlein, O. Atherosclerosis—A matter of unresolved inflammation. Semin. Immunol. 2015, 27, 184–193. [CrossRef] [PubMed]Sansbury, B.E.; Spite, M. Resolution of Acute Inflammation and the Role of Resolvins in Immunity, Thrombosis, and Vascular Biology. Circ. Res. 2016, 119, 113–130. [CrossRef] [PubMed]Kain, V.; Van Der Pol, W.; Mariappan, N.; Ahmad, A.; Eipers, P.; Morrow, C.; Gibson, D.L.; Gladine, C.; Vigor, C.; Durand, T.; et al. Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio leading to inflamed milieu in acute heart failure. FASEB J. 2019, 33, 6456–6469. [CrossRef]Chatterjee, A.; Sharma, A.; Chen, M.; Toy, R.; Mottola, G.; Conte, M.S. The Pro-Resolving Lipid Mediator Maresin 1 (MaR1) Attenuates Inflammatory Signaling Pathways in Vascular Smooth Muscle and Endothelial Cells. PLoS ONE 2014, 9, e113480. [CrossRef]Cherpokova, D.; Jouvene, C.C.; Libreros, S.; DeRoo, E.P.; Chu, L.; De La Rosa, X.; Norris, P.C.; Wagner, D.D.; Serhan, C.N. Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood 2019, 134, 1458–1468. [CrossRef] [PubMed]Miyahara, T.; Runge, S.; Chatterjee, A.; Chen, M.; Mottola, G.; Fitzgerald, J.M.; Serhan, C.N.; Conte, M.S. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J. 2013, 27, 2220–2232. [CrossRef]Dalli, J.; Serhan, C.N. Specific lipid mediator signatures of human phagocytes: Microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 2012, 120, e60–e72. [CrossRef]Mitchell, S.; Thomas, G.; Harvey, K.; Cottell, D.; Reville, K.; Berlasconi, G.; Petasis, N.; Erwig, L.; Rees, A.J.; Savill, J.; et al. Lipoxins, Aspirin-Triggered Epi-Lipoxins, Lipoxin Stable Analogues, and the Resolution of Inflammation: Stimulation of Macrophage Phagocytosis of Apoptotic Neutrophils In Vivo. J. Am. Soc. Nephrol. 2002, 13, 2497–2507. [CrossRef]Petri, M.H.; Laguna-Fernández, A.; Gonzalez-Diez, M.; Paulsson-Berne, G.; Hansson, G.K.; Bäck, M. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc. Res. 2015, 105, 65–74. [CrossRef]Norling, L.V.; Dalli, J.; Flower, R.J.; Serhan, C.N.; Perretti, M. Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci: Receptor-dependent actions. Arter. Thromb. Vasc. Biol. 2012, 32, 1970–1978. [CrossRef]Spite, M.; Norling, L.V.; Summers, L.; Yang, R.; Cooper, D.; Petasis, N.A.; Flower, R.J.; Perretti, M.; Serhan, C.N. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461, 1287–1291. [CrossRef] [PubMed]Roig, C.S.; Daemen, M.; Lutgens, E.; Soehnlein, O.; Hartwig, H. Neutrophils in atherosclerosis. A brief overview. Hamostaseologie 2015, 35, 121–127. [CrossRef] [PubMed]Zhang, P.; Yin, Y.; Wang, T.; Li, W.; Li, C.; Zeng, X.; Yang, W.; Zhang, R.; Tang, Y.; Shi, L.; et al. Maresin 1 mitigates concanavalin A-induced acute liver injury in mice by inhibiting ROS-mediated activation of NF-κB signaling. Free Radic. Biol. Med. 2020, 147, 23–36. [CrossRef]Zhuang, Y.; Liu, H.; Zhou, X.E.; Verma, R.K.; De Waal, P.W.; Jang, W.; Xu, T.-H.; Wang, L.; Meng, X.; Zhao, G.; et al. Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling. Nat. Commun. 2020, 11, 885. [CrossRef]Romano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015, 760, 49–63. [CrossRef] [PubMed]Romano, M.; Cianci, E.; Simiele, F.; Recchiuti, A. Lipoxins and aspirin-triggered lipoxins in resolution of inflammation. Eur. J. Pharmacol. 2015, 760, 49–63. [CrossRef] [PubMed]Elajami, T.K.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N.; Welty, F.K. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J. 2016, 30, 2792–2801. [CrossRef]Mottola, G.; Chatterjee, A.; Wu, B.; Chen, M.; Conte, M.S. Aspirin-triggered resolvin D1 attenuates PDGF-induced vascular smooth muscle cell migration via the cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) pathway. PLoS ONE 2017, 12, e0174936. [CrossRef]Bennett, M.R.; Sinha, S.; Owens, G.K. Vascular Smooth Muscle Cells in Atherosclerosis. Circ. Res. 2016, 118, 692–702. [CrossRef]Nakayama, A.; Albarrán-Juárez, J.; Liang, G.; Roquid, K.A.; Iring, A.; Tonack, S.; Chen, M.; Müller, O.J.; Weinstein, L.S.; Offermanns, S. Disturbed flow–induced Gs-mediated signaling protects against endothelial inflammation and atherosclerosis. JCI Insight 2020, 5, 140485. [CrossRef]Fredman, G.; Hellmann, J.; Proto, J.D.; Kuriakose, G.; Colas, R.A.; Dorweiler, B.; Connolly, E.S.; Solomon, R.; Jones, D.M.; Heyer, E.J.; et al. An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat. Commun. 2016, 7, 12859. [CrossRef]Lee, H.-N.; Surh, Y.-J. Resolvin D1-mediated NOX2 inactivation rescues macrophages undertaking efferocytosis from oxidative stress-induced apoptosis. Biochem. Pharmacol. 2013, 86, 759–769. [CrossRef] [PubMed]Fredman, G.; Ozcan, L.; Spolitu, S.; Hellmann, J.; Spite, M.; Backs, J.; Tabas, I. Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway. Proc. Natl. Acad. Sci. USA 2014, 111, 14530–14535. [CrossRef] [PubMed]Doran, A.C.; Yurdagul, A.; Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 2019, 20, 254–267. [CrossRef] [PubMed]Cai, B.; Thorp, E.B.; Doran, A.C.; Subramanian, M.; Sansbury, B.E.; Lin, C.-S.; Spite, M.; Fredman, G.; Tabas, I. MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation. Proc. Natl. Acad. Sci. USA 2016, 113, 6526–6531. [CrossRef]Rymut, N.; Heinz, J.; Sadhu, S.; Hosseini, Z.; Riley, C.O.; Marinello, M.; Maloney, J.; MacNamara, K.C.; Spite, M.; Fredman, G. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 2019, 34, 597–609. [CrossRef]Hosseini, Z.; Marinello, M.; Decker, C.; Sansbury, B.E.; Sadhu, S.; Gerlach, B.D.; Ramos, R.B.; Adam, A.P.; Spite, M.; Fredman, G. Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation. Arter. Thromb. Vasc. Biol. 2021, 41, 1062–1075. [CrossRef]Schif-Zuck, S.; Gross, N.; Assi, S.; Rostoker, R.; Serhan, C.N.; Ariel, A. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: Modulation by resolvins and glucocorticoids. Eur. J. Immunol. 2011, 41, 366–379. [CrossRef]Dalli, J.; Winkler, J.W.; Colas, R.A.; Arnardottir, H.; Cheng, C.-Y.C.; Chiang, N.; Petasis, N.A.; Serhan, C.N. Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Potent Immunoresolvents. Chem. Biol. 2013, 20, 188–201. [CrossRef]Welty, F.K.; Schulte, F.; Alfaddagh, A.; Elajami, T.K.; Bistrian, B.R.; Hardt, M. Regression of human coronary artery plaque is associated with a high ratio of (18-hydroxy-eicosapentaenoic acid + resolvin E1) to leukotriene B 4. FASEB J. 2021, 35, e21448. [CrossRef]Wu, B.; Mottola, G.; Schaller, M.; Upchurch, G.R.; Conte, M.S. Resolution of vascular injury: Specialized lipid mediators and their evolving therapeutic implications. Mol. Asp. Med. 2017, 58, 72–82. [CrossRef]Efremova, O.A.; Starodubov, O.D.; Kamyshnikova, L.A.; Bolkhovitina, O.A.; Obolonkova, N.I. Clinical-functional changes of myocardium after percutaneous coronary interventions in patients with chronic heart failure. Lat. Hipertens. 2019, 14, 256–261.Shah, P.K. Inflammation, Neointimal Hyperplasia, and Restenosis. Circulation 2003, 107, 2175–2177. [CrossRef] [PubMed]Newby, A.C.; Zaltsman, A.B. Molecular mechanisms in intimal hyperplasia. J. Pathol. 2000, 190, 300–309. [CrossRef]Conte, M.S.; Desai, T.A.; Wu, B.; Schaller, M.; Werlin, E. Pro-resolving lipid mediators in vascular disease. J. Clin. Investig. 2018, 128, 3727–3735. [CrossRef]Liu, G.; Gong, Y.; Zhang, R.; Piao, L.; Li, X.; Liu, Q.; Yan, S.; Shen, Y.; Guo, S.; Zhu, M.; et al. Resolvin E1 attenuates injury-induced vascular neointimal formation by inhibition of inflammatory responses and vascular smooth muscle cell migration. FASEB J. 2018, 32, 5413–5425. [CrossRef]Petri, M.H.; Laguna-Fernandez, A.; Tseng, C.-N.; Hedin, U.; Perretti, M.; Bäck, M. Aspirin-triggered 15-epi-lipoxin A4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int. J. Cardiol. 2015, 179, 370–372. [CrossRef]Akagi, D.; Chen, M.; Toy, R.; Chatterjee, A.; Conte, M.S. Systemic delivery of proresolving lipid mediators resolvin D 2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J. 2015, 29, 2504–2513. [CrossRef]Wu, B.; Mottola, G.; Chatterjee, A.; Lance, K.D.; Chen, M.; Siguenza, I.O.; Desai, T.A.; Conte, M.S. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J. Vasc. Surg. 2016, 65, 207–217.e3. [CrossRef]Wu, B.; Mottola, G.; Chatterjee, A.; Lance, K.D.; Chen, M.; Siguenza, I.O.; Desai, T.A.; Conte, M.S. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J. Vasc. Surg. 2016, 65, 207–217.e3. [CrossRef]Yang, M.; Chen, Q.; Mei, L.; Wen, G.; An, W.; Zhou, X.; Niu, K.; Liu, C.; Ren, M.; Sun, K.; et al. Neutrophil elastase promotes neointimal hyperplasia by targeting toll-like receptor 4 (TLR4)-NF-κB signalling. Br. J. Pharmacol. 2021, 178, 4048–4068. [CrossRef]Li, Y.; Wang, N.; Ma, Z.; Wang, Y.; Yuan, Y.; Zhong, Z.; Hong, Y.; Zhao, M. Lipoxin A4 protects against paraquat-induced acute lung injury by inhibiting the TLR4/MyD88-mediated activation of the NF-κB and PI3K/AKT pathways. Int. J. Mol. Med. 2021, 47, 86. [CrossRef] [PubMedLiu, Z.; Qu, M.; Yang, Q.; Chang, Y. Lipoxin A4 ameliorates renal ischaemia–reperfusion-induced acute lung injury in rats. Clin. Exp. Pharmacol. Physiol. 2019, 46, 65–74. [CrossRef] [PubMed]Liu, R.; Li, Z.; Wang, Q. Resolvin D1 Attenuates Myocardial Infarction in a Rodent Model with the Participation of the HMGB1 Pathway. Cardiovasc. Drugs Ther. 2019, 33, 399–406. [CrossRef] [PubMed]Pan, H.; Xue, C.; Auerbach, B.J.; Fan, J.; Bashore, A.C.; Cui, J.; Yang, D.Y.; Trignano, S.B.; Liu, W.; Shi, J.; et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation 2020, 142, 2060–2075. [CrossRef]Pan, H.; Xue, C.; Auerbach, B.J.; Fan, J.; Bashore, A.C.; Cui, J.; Yang, D.Y.; Trignano, S.B.; Liu, W.; Shi, J.; et al. Single-Cell Genomics Reveals a Novel Cell State During Smooth Muscle Cell Phenotypic Switching and Potential Therapeutic Targets for Atherosclerosis in Mouse and Human. Circulation 2020, 142, 2060–2075. [CrossRef]Feil, S.; Fehrenbacher, B.; Lukowski, R.; Essmann, F.; Schulze-Osthoff, K.; Schaller, M.; Feil, R. Transdifferentiation of Vascular Smooth Muscle Cells to Macrophage-Like Cells During Atherogenesis. Circ. Res. 2014, 115, 662–667. [CrossRef]Yang, J.; Li, M.; Hu, X.; Lu, J.; Wang, Q.; Lu, S.; Gao, F.; Jin, S.; Zheng, S. Protectin DX promotes epithelial injury repair and inhibits fibroproliferation partly via ALX/PI3K signalling pathway. J. Cell. Mol. Med. 2020, 24, 14001–14012. [CrossRef]Zheng, S.; Wang, Q.; D’Souza, V.; Bartis, D.; Dancer, R.; Parekh, D.; Gao, F.; Lian, Q.; Jin, S.; Thickett, D.R. ResolvinD1 stimulates epithelial wound repair and inhibits TGF-β-induced EMT whilst reducing fibroproliferation and collagen production. Lab. Investig. 2018, 98, 130–140. [CrossRef]Zheng, S.; D’Souza, V.K.; Bartis, D.; Dancer, R.C.; Parekh, D.; Naidu, B.; Gao-Smith, F.; Wang, Q.; Jin, S.; Lian, Q.; et al. Lipoxin A4promotes lung epithelial repair whilst inhibiting fibroblast proliferation. ERJ Open Res. 2016, 2, 00079–02015. [CrossRef]Frank, A.; Bonney, M.; Bonney, S.; Weitzel, L.; Koeppen, M.; Eckle, T. Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Semin. Cardiothorac. Vasc. Anesth. 2012, 16, 123–132. [CrossRef]Wu, M.-Y.; Yiang, G.-T.; Liao, W.-T.; Tsai, A.P.Y.; Cheng, Y.-L.; Cheng, P.-W.; Li, C.-Y.; Li, C.J. Current Mechanistic Concepts in Ischemia and Reperfusion Injury. Cell. Physiol. Biochem. 2018, 46, 1650–1667. [CrossRef] [PubMed]Chen, Z.; Wu, Z.; Huang, C.; Zhao, Y.; Zhou, Y.; Zhou, X.; Lu, X.; Mao, L.; Li, S. Effect of Lipoxin A4 on Myocardial Ischemia Reperfusion Injury Following Cardiac Arrest in a Rabbit Model. Inflammation 2013, 36, 468–475. [CrossRef] [PubMed]Chen, X.-Q.; Wu, S.-H.; Zhou, Y.; Tang, Y.-R. Involvement of K+ channel-dependant pathways in lipoxin A4-induced protective effects on hypoxia/reoxygenation injury of cardiomyocytes. Prostaglandins Leukot. Essent. Fat. Acids 2013, 88, 391–397. [CrossRef] [PubMed]Zheng, J.; Chen, P.; Zhong, J.; Cheng, Y.; Chen, H.; He, Y.; Chen, C. HIF-1α in myocardial ischemia-reperfusion injury. Mol. Med. Rep. 2021, 23, 352. [CrossRef]Zhao, Q.; Shao, L.; Hu, X.; Wu, G.; Du, J.; Xia, J.; Qiu, H. Lipoxin A4Preconditioning and Postconditioning Protect Myocardial Ischemia/Reperfusion Injury in Rats. Mediat. Inflamm. 2013, 2013, e231351. [CrossRef] [PubMed]Cheng, Y.; Rong, J. Pro-resolving lipid mediators as therapeutic leads for cardiovascular diseases. Expert Opin. Ther. Targets 2019, 23, 423–436. [CrossRef]Halade, G.V.; Norris, P.C.; Kain, V.; Serhan, C.N.; Ingle, K.A. Splenic leukocytes define the resolution of inflammation in heart failure. Sci. Signal. 2018, 11, eaao1818. [CrossRef]Halade, G.V.; Kain, V.; Dillion, C.; Beasley, M.; Dudenbostel, T.; Oparil, S.; Limdi, N.A. Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction. ESC Heart Fail. 2020, 7, 1700–1710. [CrossRef]Tourki, B.; Kain, V.; Pullen, A.B.; Norris, P.C.; Patel, N.; Arora, P.; Leroy, X.; Serhan, C.N.; Halade, G.V. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure. Mol. Metab. 2020, 31, 138–149. [CrossRef]Keyes, K.T.; Ye, Y.; Lin, Y.; Zhang, C.; Perez-Polo, J.R.; Gjorstrup, P.; Birnbaum, Y. Resolvin E1 protects the rat heart against reperfusion injury. Am. J. Physiol. Circ. Physiol. 2010, 299, H153–H164. [CrossRef]Gilbert, K.; Bernier, J.; Godbout, R.; Rousseau, G. Resolvin D1, a Metabolite of Omega-3 Polyunsaturated Fatty Acid, Decreases Post-Myocardial Infarct Depression. Mar. Drugs 2014, 12, 5396–5407. [CrossRef] [PubMed]Gilbert, K.; Bernier, J.; Bourque-Riel, V.; Malick, M.; Rousseau, G. Resolvin D1 Reduces Infarct Size Through a Phosphoinositide 3-Kinase/Protein Kinase B Mechanism. J. Cardiovasc. Pharmacol. 2015, 66, 72–79. [CrossRef] [PubMed]Kain, V.; Ingle, K.A.; Colas, R.A.; Dalli, J.; Prabhu, S.D.; Serhan, C.N.; Joshi, M.D.; Halade, G.V. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J. Mol. Cell. Cardiol. 2015, 84, 24–35. [CrossRef] [PubMed]Orr, S.K.; Colas, R.A.; Dalli, J.; Chiang, N.; Serhan, C.N. Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent. Am. J. Physiol. Cell. Mol. Physiol. 2015, 308, L904–L911. [CrossRef]Pirault, J.; Bäck, M. Lipoxin and Resolvin Receptors Transducing the Resolution of Inflammation in Cardiovascular Disease. Front. Pharmacol. 2018, 9, 1273. [CrossRef]Sánchez-Hernández, C.D.; Torres-Alarcón, L.A.; González-Cortés, A.; Peón, A.N. Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. Mediat. Inflamm. 2020, 2020, e8405370. [CrossRef]Heinz, J.; Marinello, M.; Fredman, G. Pro-resolution therapeutics for cardiovascular diseases. Prostaglandins Other Lipid Mediat. 2017, 132, 12–16. [CrossRef]Hasturk, H.; Abdallah, R.; Kantarci, A.; Nguyen, D.; Giordano, N.; Hamilton, J.; Van Dyke, T.E. Resolvin E1 (RvE1) Attenuates Atherosclerotic Plaque Formation in Diet and Inflammation-Induced Atherogenesis. Arter. Thromb. Vasc. Biol. 2015, 35, 1123–1133. [CrossRef]Salic, K.; Morrison, M.C.; Verschuren, L.; Wielinga, P.Y.; Wu, L.; Kleemann, R.; Gjorstrup, P.; Kooistra, T. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 2016, 250, 158–165. [CrossRef]Petri, M.H.; Laguna-Fernandez, A.; Arnardottir, H.; Wheelock, C.E.; Perretti, M.; Hansson, G.K.; Bäck, M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br. J. Pharmacol. 2017, 174, 4043–4054. [CrossRef] [PubMed]Makino, Y.; Miyahara, T.; Nitta, J.; Miyahara, K.; Seo, A.; Kimura, M.; Suhara, M.; Akai, A.; Akagi, D.; Yamamoto, K.; et al. Proresolving Lipid Mediators Resolvin D1 and Protectin D1 Isomer Attenuate Neointimal Hyperplasia in the Rat Carotid Artery Balloon Injury Model. J. Surg. Res. 2019, 233, 104–110. [CrossRef] [PubMed]Thul, S.; Labat, C.; Temmar, M.; Benetos, A.; Bäck, M. Low salivary resolvin D1 to leukotriene B4 ratio predicts carotid intima media thickness: A novel biomarker of non-resolving vascular inflammation. Eur. J. Prev. Cardiol. 2017, 24, 903–906. [CrossRef] [PubMed]Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T., Jr.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med. 2019, 380, 11–22. [CrossRef] [PubMed]Gromovsky, A.D.; Schugar, R.C.; Brown, A.L.; Helsley, R.N.; Burrows, A.C.; Ferguson, D.; Zhang, R.; Sansbury, B.E.; Lee, R.G.; Morton, R.E.; et al. ∆-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arter. Thromb. Vasc. Biol. 2018, 38, 218–231. [CrossRef]Skarke, C.; Alamuddin, N.; Lawson, J.A.; Li, X.; Ferguson, J.F.; Reilly, M.P.; FitzGerald, G.A. Bioactive products formed in humans from fish oils. J. Lipid Res. 2015, 56, 1808–1820. [CrossRef] [PubMed]Bäck, M.; Yurdagul, A., Jr.; Tabas, I.; Öörni, K.; Kovanen, P.T. Inflammation and its resolution in atherosclerosis: Mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2019, 16, 389–406. [CrossRef]Zhou, X.; Cai, J.; Liu, W.; Wu, X.; Gao, C. Cysteinyl leukotriene receptor type 1 (CysLT1R) antagonist zafirlukast protects against TNF-α-induced endothelial inflammation. Biomed. Pharmacother. 2019, 111, 452–459. [CrossRef]Medina-Leyte, D.; Zepeda-García, O.; Domínguez-Pérez, M.; González-Garrido, A.; Villarreal-Molina, T.; Jacobo-Albavera, L. Endothelial Dysfunction, Inflammation and Coronary Artery Disease: Potential Biomarkers and Promising Therapeutical Approaches. Int. J. Mol. Sci. 2021, 22, 3850. [CrossRef]Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131. [CrossRef]Ridker, P.M.; Everett, B.M.; Pradhan, A.; MacFadyen, J.G.; Solomon, D.H.; Zaharris, E.; Mam, V.; Hasan, A.; Rosenberg, Y.; Iturriaga, E.; et al. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N. Engl. J. Med. 2019, 380, 752–762. [CrossRef] [PubMed]Chávez-Castillo, M.; Ortega, A.; Cudris-Torres, L.; Duran, P.; Rojas, M.; Manzano, A.; Garrido, B.; Salazar, J.; Silva, A.; Rojas- Gomez, D.M.; et al. Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy? Int. J. Mol. Sci. 2021, 22, 10370. [CrossRef] [PubMed]Gila-Diaz, A.; Carrillo, G.; Singh, P.; Ramiro-Cortijo, D. Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases. Antioxidants 2021, 10, 933. [CrossRef] [PubMed]Morales Aguilar, R.; Lastre-Amell, G.; Pardo Vásquez, A. Estilos de vida relacionados con factores de riesgo cardiovascular. AVFT Arch. Venez. Farm. Ter. 2018, 37, 50–62.Verónica Mora, D.E.; Morr, C.; Paciotti, S.; Prospert, O.P.; Quiroz, J. Células inflamatorias en lesiones ateroescleróticas de las arterias coronarias humanas. Gac. Médica Caracas 2020, 124, 298–307.Espinoza, R.; Arab, G.; Wiliam, Z.; Carrasquero, L.; Subero, L.; Colina, R.; Ana, T.; Jorge, P.; José, T.; Antonio, V.; et al. Evaluación de la incidencia de trombosis coronaria post Stent, posterior a la comercialización de segundas marcas de Clopidogrel. Hospital Miguel Pérez Carreño. Caracas. Venezuela. AVFT Arch. Venez. Farm. Ter. 2015, 33, 7–12.Bermúdez Arias, D.F. La recuperación del miocardio hibernado mejora el pronóstico de la cardiopatía isquémica metabólica. Gac. Médica Caracas 2020, 113, 19–41.Ayala, J.; López, C.; Hong, A.; Oberto, C.; Paiva, A.; Lares, M. Efecto de los ácidos grasos poliinsaturados (omega 3) sobre la agregación plaquetaria. Lat. Hipertens. 2009, 4, 71–78.ORIGINAL2022_MDPI_Spec Proresolving Lipid.pdf2022_MDPI_Spec Proresolving Lipid.pdfPDFapplication/pdf1241511https://bonga.unisimon.edu.co/bitstreams/77ebab91-2782-45fe-9fc8-78397fb44701/download6920618a1c5997240d35e7cb8171ea47MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/8fd080b9-e285-41e7-9134-d3b7dedd7504/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/48ca96bc-186b-4d28-bd70-ae4851ee28c6/download733bec43a0bf5ade4d97db708e29b185MD53TEXT2022_MDPI_Spec Proresolving Lipid.pdf.txt2022_MDPI_Spec Proresolving Lipid.pdf.txtExtracted texttext/plain100415https://bonga.unisimon.edu.co/bitstreams/ea651e9f-21de-47fe-8c3e-dd5d8c431211/download5e974b4c06cbb4648ab82c51491feb22MD54THUMBNAIL2022_MDPI_Spec Proresolving Lipid.pdf.jpg2022_MDPI_Spec Proresolving Lipid.pdf.jpgGenerated Thumbnailimage/jpeg5750https://bonga.unisimon.edu.co/bitstreams/0f90e57a-28ab-40fe-96ef-b43c4e5805ec/downloadee68bde9bfb94a66dd6b4a47aeea4c7aMD5520.500.12442/11286oai:bonga.unisimon.edu.co:20.500.12442/112862024-04-19 15:05:06.085http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coDSpace UniSimonbibliotecas@biteca.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 |